A Synthetic Shuttle for Cytosolic Drug Delivery in Cancer Therapy

Many of the most critical cancer drivers are located inside tumor cells, yet existing therapies often struggle to effectively and selectively deliver drugs into the cytosol in vivo. As a result, key intracellular cancer targets remain largely inaccessible. The iDEL platform enables direct cytosolic delivery of diverse therapeutic payloads, spanning small and large molecules, into patients’ tumor cells through a unique, uptake mechanism upregulated in tumors. This mechanism has been observed to be highly active in multiple cancer types, supporting a broad potential application in solid tumors.

Jürgen Moll is the Chief Scientific Officer iDEL Therapeutics GmbH - Dortmund, Germany